CRP and COVID-19: An open-label study from Italy including 56 patients with severe COVID-19 showed that after 28 days of follow-up, sarilumab treatment (n = 28) appeared to promote the recovery of patients with mild lung consolidation (<17%) at baseline.248 Another retrospective, single-center, clinical trial from Italy including 15 COVID-19 patients showed that sarilumab treatment improved the clinical symptoms and reduced serum CRP levels in most patients (n = 10).249 Currently, a total of 17 clinical trials on sarilumab are registered in ClinicalTrials.gov for the treatment of COVID-19.